Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.

Autor: Mittal K; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Cooper GW; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Lee BP; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Su Y; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Skinner KT; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Shim J; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Jonus HC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Kim WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doshi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Almanza D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kynnap BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Christie AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Yang X; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cowley GS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Morton CL; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA., Dwivedi B; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Lawrence T; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Rupji M; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Keskula P; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Meyer S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Clinton CM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bhasin M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Crompton BD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tseng YY; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boehm JS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ligon KL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Murphy AJ; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck & Co., Rahway, NJ, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Spangle JM; Winship Cancer Institute, Emory University, Atlanta, GA, USA.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA., Rivera MN; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Mullen EA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stegmaier K; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Goldsmith KC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. william_hahn@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. william_hahn@dfci.harvard.edu., Hong AL; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. andrew.hong2@emory.edu.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. andrew.hong2@emory.edu.; Winship Cancer Institute, Emory University, Atlanta, GA, USA. andrew.hong2@emory.edu.

Publikováno v: Communications biology [Commun Biol] 2024 Apr 08; Vol. 7 (1), pp. 426. Date of Electronic Publication: 2024 Apr 08.

Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer.

Autor: Baker SC; Jack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK. simon.baker@york.ac.uk., Mason AS; Jack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK., Slip RG; Jack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK., Skinner KT; Jack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK., Macdonald A; Faculty of Biological Sciences, School of Molecular and Cellular Pathology, University of Leeds, Leeds, UK., Masood O; Leeds Kidney Unit, St James's University Hospital, Leeds, UK., Harris RS; College of Biological Sciences, University of Minnesota, Minneapolis, MN, 55455, USA., Fenton TR; School of Biosciences, University of Kent, Canterbury, CT2 7NJ, UK.; School of Cancer Sciences, Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK., Periyasamy M; Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London, UK.; Disease Intervention Technology Laboratory (DITL), Institute of Molecular and Cell Biology (IMCB), 8A Biomedical Grove, Neuros/Immunos, #06-04/05, Singapore, 138648, Singapore., Ali S; Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London, UK., Southgate J; Jack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK.

Publikováno v: Oncogene [Oncogene] 2022 Apr; Vol. 41 (15), pp. 2139-2151. Date of Electronic Publication: 2022 Feb 22.